tinic acid is not well defined, and several mechanisms have recently been described (8, 17) . Frank deficiency of nicotinic acid in humans is rare, but when it occurs leads to pellagra, a disease characterized by inflammation of mucous membranes, skin lesions, and diarrhea (5, 31) . Nicotinic acid deficiency and suboptimal levels have been reported in patients with Hartnup's disease and in alcoholics (15, 20, 23, 31) . Patients with Hartnup disease have mutations in the gene that encodes the membrane transporter of the amino acid tryptophan, which is an endogenous precursor of nicotinic acid.
Humans obtain nicotinic acid from two sources: an exogenous source where the vitamin is obtained from the diet via intestinal absorption and an endogenous source where the vitamin is produced (when the exogenous supply of the vitamin is low) via the metabolic conversion of tryptophan (1, 14) . Nicotinic acid is distributed to different body tissues via the circulation, where the vitamin exists in plasma at levels of 0.1-1 M (9, 29). The liver plays an important role in the metabolism of exogenous nicotinic acid (3) , and both in vivo and in vitro studies have shown significant uptake of administered vitamin by hepatocytes (3, 16) . Little, however, is known about the mechanism(s) by which liver cells transport negatively charged (pKa ϭ 4.9) nicotinic acid. A low-affinity and nonspecific nicotinic acid membrane transport system(s) has been proposed to function in a number of tissues, including the intestine (2, 6, 7, 22, 28 -30) , but the importance of such a system(s) in transporting physiological concentrations of the vitamin is not clear. A recent study (22) has reported the existence of a high-affinity system for nicotinic acid uptake in human intestinal epithelial cells. This system was found to function at the physiological (micromolar) concentration range of the vitamin and is specific for nicotinic acid. In addition to providing a challenge to the previous belief that the intestinal nicotinic acid uptake process involves a nonspecific low-affinity uptake system (7, 22, 28, 30) , these findings have also raised the possibility that a similar uptake process may function in other cell types if the proper conditions are used to study the vitamin uptake event. Our aim in the present study was, therefore, to to test this possibility in human hepatocytes using both human-derived liver HepG2 cells and human primary hepatocytes as models. The results showed, for the first time, that human heptocytes do indeed have a specific high-affinity carrier system for nicotinic acid uptake, which most likely is the system responsible for the uptake of physiological concentrations of the vitamin. The results also showed the system to be pH dependent and appears to be under the regulation of an intracellular Ca 2ϩ /calmodulinmediated pathway.
MATERIALS AND METHODS
[ 3 H]nicotinic acid (specific activity: 50 Ci/mmol, radiochemical purity: 97%) was obtained from American Radiolabeled Chemicals (St. Louis, MO). Culture medium (DMEM) and other cell culture ingredients were obtained from Sigma (St. Louis, MO). All other chemicals and reagents used in this investigation were of analytical grade and were obtained from commercial sources.
The human-derived liver HepG2 cells (passages 10 -20, American Type Culture Collection, Manassas, VA) used in this investigation were grown to confluence in DMEM growth medium containing 10% FBS. Uptake experiments were performed on monolayers 3-5 days after confluence. When human primary hepatocytes were used, they were obtained in 24 at 37°C (unless otherwise stated) in the presence of labeled and unlabeled nicotinic acid. Uptake was terminated at the appropriate time point by the addition of ice-cold buffer (ϫ2) followed by immediate aspiration and rinsing. Cells were then digested with 1 ml of 1 N NaOH, neutralized with HCl, and then counted for radioactivity. A Bio-Rad kit (Richmond, VA) was used to measure the protein content of cell digests.
In examining the metabolic form of the transported substrate following incubation of HepG2 cells with [ 3 H]nicotinic acid (18 nM), Silica-precoated thin-layer chromatography plates and a solvent system of 4:4:2 (vol/vol/vol) ratio of n-butanol, acetic acid, and water were used. When the effect of substrate level in the growth medium on the initial rate of [ 3 H]nicotinic acid uptake was examined, HepG2 cells were maintained for 48 h in the absence or presence of nicotinic acid or nicotinimide (each at 1 mM) and then used for uptake investigations.
Data presentation and statistical analysis. Transport data are means Ϯ SE of multiple separate uptake determinations and were expressed in terms of femtomoles or picomoles per milligram protein per unit time. Variability in the absolute amount of nicotinic acid taken up by HepG2 cells and human primary hepatocytes was observed in different batches of HepG2 cells and different individual human donors. For this reason, appropriate controls were run simultaneously with each set of experiments for comparison. Transport of nicotinic acid by the carrier-mediated process was calculated by subtracting the passive diffusion component (determined from the slope of the uptake line between 10 mM nicotinic acid and the point of origin, i.e., multiplication of the slope by the individual concentration) from total uptake at each concentration examined. Kinetic parameters of the saturable folic acid uptake process were calculated using a computerized model as previously described (25) . Statistical analysis was performed using Student's t-test and ANOVA, with statistical significance being set at 0.05 (P Ͻ 0.05).
RESULTS

Basic characteristics of nicotinic acid transport in HepG2 cells.
The initial rate (3 min, see below) of nicotinic acid (6 nM) transport into HepG2 cells was temperature dependent, as a significant (P Ͻ 0.01) decrease in transport was found upon lowering the incubation temperature from 37 to 22°C (389 Ϯ 29 and 105.8 Ϯ 5.8 fmol ⅐ mg protein Ϫ1 ⅐ 3 min Ϫ1 , respectively). Also, transport of the vitamin into HepG2 cells was energy dependent, as significant (P Ͻ 0.01 for both) inhibition in the initial rate of nicotinic acid (6 nM) transport was observed following pretreatment (for 30 min) of cells with the metabolic inhibitors iodoacetate (0.5 mM) and 2,4-dinitrophenol (1 mM) (436 Ϯ 24, 293.7 Ϯ 13.7, and 236 Ϯ 10 fmol ⅐ mg protein Ϫ1 ⅐ 3 min
Ϫ1
for control and following pretreatment with iodoacetate and 2,4-dinitrophenol, respectively). Furthermore, uptake of nicotinic acid by HepG2 cells proceeded without metabolic alterations in the transported substrate (92.3% and 91.2% of the transported radioactivity following 7-and 10-min incubation of cells with 18 nM [ 3 H]nicotinic acid, respectively) and was found to be in the form of nicotinic acid (see MATERIALS AND METHODS). Moreover, transport of low (0.1 M) and high (10 M) concentrations of nicotinic acid into HepG2 cells was linear with time for up to 10 min of incubation ( Fig. 1) , which was the reason behind our selection of a 3-min period as the standard incubation time in all experiments. 
Role of H ϩ and Na ϩ in the transport of nicotinic acid in HepG2 cells and human primary hepatocytes. The role of extracellular H
ϩ in the transport of nicotinic acid into HepG2 cells was studied by examining the effect of varying incubation buffer pH over the range of 8.0 to 5.0 on the initial rate of vitamin uptake. A sharp increase in nicotinic acid (6 nM) uptake was observed upon decreasing the incubation buffer pH from 8.0 to 5.0 (Fig. 2) . Uptake of nicotinic acid at buffer pH 5.0 was ϳ28-fold higher than uptake at buffer pH 8.0. In a related investigation, we examined the effect of pretreatment of (for 30 min, buffer pH 5.0) HepG2 cells with the protonophore FCCP (50 M) on the initial rate of uptake of 6 nM nicotinic acid. FCCP significantly (P Ͻ 0.01) inhibited nicotinic acid uptake (407 Ϯ 13.5 and 182.8 Ϯ 14.8 fmol ⅐ mg protein Ϫ1 ⅐ 3 min Ϫ1 for control and FCCP-pretreated cells, respectively).
When the effect of incubation buffer pH on [ 3 H]nicotinic acid (12 nM) transport into human primary hepatocytes was examined, a significantly (P Ͻ 0.01, 7.2-fold) higher vitamin uptake was again observed at buffer pH 5.0 compared with 7.4 (5.3 Ϯ 0.16 and 0.74 Ϯ 0.05 pmol ⅐ mg protein Ϫ1 ⅐ 3 min Ϫ1 , respectively). Pretreatment (for 30 min, buffer pH 5.0) with FCCP (50 M) also caused a significant (P Ͻ 0.01) inhibition in the initial rate of nicotinic acid (12 nM) uptake by human primary hepatocytes (1.35 Ϯ 0.05 and 0.18 Ϯ 0.01 pmol ⅐ mg protein Ϫ1 ⅐ 3 min Ϫ1 for control and FCCP-pretreated cells, respectively). As demonstrated by these results, the absolute amount of nicotinic acid uptake by human primary hepatocytes was markedly higher than that by HepG2 cells. Because of this, buffer pH 5.0 was used in all our investigations.
The role of extracellular Na ϩ in driving the initial rate of uptake of nicotinic acid by HepG2 cells was examined by testing the effect of replacement of Na ϩ with an eqimolar concentration of the monovalent cations K ϩ and Li ϩ or with mannitol on the vitamin (6 nM) uptake by process. Similar nicotinic acid uptake was found in the presence and absence of Na ϩ (379.3 Ϯ 14.7, 371.3 Ϯ 19.6, 375.5 Ϯ 39, and 365 Ϯ 26 fmol ⅐ mg protein Ϫ1 ⅐ 3 min Ϫ1 in the presence of Na ϩ , K ϩ , Li ϩ , and mannitol, respectively). In a related experiment, we examined the effect of ouabain (1 mM), an inhibitor of Na ϩ -K ϩ -ATPase, on the initial rate of nicotinic acid (6 nM) uptake. The results showed a lack of significant effect of ouabain on vitamin uptake (435.8 Ϯ 24 and 416.7 Ϯ 19 fmol ⅐ mg protein Ϫ1 ⅐ 3 min Ϫ1 for control and ouabainpretreated cells, respectively).
Involvement of a carrier-mediated system for nicotinic acid transport in HepG2 cells and human primary hepatocytes.
The initial rate of nicotinic acid transport into HepG2 cells was examined as a function of concentration over a wide range of substrate concentrations spanning nanomolar and micromolar ranges (6 nM-10 M), i.e., spanning the entire physiological range. We observed saturation in the initial rate of nicotinic acid uptake in the micromolar range only (Fig. 3) . Kinetic parameters of the saturable process were determined as described in MATERIALS We also examined the effect of unlabeled nicotinic acid (500 M) in the incubation medium on The effect of the membrane transport inhibitors phloretin, ␣-cyano-4-hydroxycinnamate, SITS, DIDS, probenecid, and furosemide (all at 1 mM) on the initial rate of nicotinic acid (6 nM) uptake by HepG2 cells was also examined. None of the tested compounds were found to affect nicotinic acid uptake (Table 3) .
Possible regulation of the nicotinic acid uptake process of human liver cells. Possible regulation of the nicotinic acid uptake process of human liver cells by intracellular and extracellular factors was investigated. The effect of intracellular factors was examined by testing the effect of pretreatment of HepG2 cells with specific modulators of the PKA-, PKC-, protein tyrosine kinase (PTK)-, and Ca 2ϩ /calmodulinmediated regulatory pathways on the initial rate of uptake of nicotinic acid (6 nM). The results showed that all the PKC-mediated pathway modulators used had no effect on nicotinic acid (6 nM) uptake (Table 4) . Similarly, modulators of the PKA-mediated pathway [8-bromo-cAMP (1 mM), forskolin (0.1 mM), IBMX (1 mM), and H89 (1 mM)] did not affect nicotinic acid (6 nM) uptake (Table 5 ). Modulators of the PTK pathway also failed to affect nicotinic acid uptake by HepG2 cells (data not shown). On the other hand, modulators of the Ca 2ϩ / calmodulin-mediated pathway (trifluoperazine and calmidazolium) were found to cause a concentration-dependent and significant (P Ͻ 0.01) inhibition in vitamin uptake (Table 2) . When the effect of Values are means Ϯ SE of at least 3 separate uptake determinations. HepG2 cells were treated as described in Table 1 . Unrelated carboxylic acids were added at the onset of incubation. Values are means Ϯ SE of at least 3 separate uptake determinations. HepG2 cells were treated as described in Table 1 . Compounds were added at the onset of incubation. Values are means Ϯ SE of at least 3 separate uptake determinations. Confluent monolayers were incubated at 37°C in Krebs-Ringer buffer (pH 5.0) in the presence of the structural analogs (nicotinamide, isonicotinic acid, nicotinyl alcohol, and nicotinuric acid) and 6 nM ͓ 3 H͔nicotinic acid. Uptake was determined after 3 min of incubation. NS, not significant. Table 4 
. Effect of pretreatment of HepG2 cells with modulators of the PKC-mediated pathway on the uptake of nicotinic acid
Condition
Uptake, fmol ⅐ mg protein Ϫ1 ⅐ 3 min
Values are means Ϯ SE of at least 3 separate uptake determinations. HepG2 cells were treated as described in Table 1 with the exception that cells were pretreated for 1 h with the different modulators.
calmidazolium (100 M) pretreatment on nicotinic acid (12 nM) uptake was examined in human primary hepatocytes, significant (P Ͻ 0.01) inhibition was also observed (3.16 Ϯ 0.1 and 1.32 Ϯ 0.08 pmol ⅐ mg protein Ϫ1 ⅐ 3 min Ϫ1 for control and in the presence of calmidazolium, respectively). These results suggest the possible involvement of a Ca 2ϩ /calmodulin-mediated pathway in the regulation of nicotinic acid uptake by human liver cells.
The effect of the extracellular nicotinate level on vitamin uptake by HepG2 cells was also investigated. HepG2 cells were maintained for 48 h in growth medium oversupplemented with either 1 mM nicotinic acid or with 1 mM nicotinamide followed by a test of the initial rate of [ 3 H]nicotinic acid (6 nM) uptake. The results showed a similar rate of [
3 H]nicotinic acid uptake under all conditions (412 Ϯ 14, 405 Ϯ 20, and 401 Ϯ 13 fmol ⅐ mg protein Ϫ1 ⅐ 3 min Ϫ1 for cells maintained in control growth medium and those maintained in growth media supplemented with nicotinic acid and nicotinamide, respectively).
DISCUSSION
We investigated the mechanism of transport of nicotinic acid into human liver cells using two cell models: human-derived liver HepG2 cells and human primary hepatocytes obtained from organ donors. Use of a cell line together with primary cells of the tissue of origin provides physiological relevance to the findings with the cell line model. Our results showed that the initial rate of the transport process in HepG2 cells is temperature and energy dependent and occurs with minimal metabolic alterations in the transported substrate. The latter suggests that metabolic trapping does not influence the initial rate of nicotinic acid uptake in these cells. Transport of nicotinic acid in both HepG2 cells and primary hepatocytes was highly dependent on extracellular pH with a significantly higher uptake of the vitamin at acidic compared with neutral or alkaline buffer pHs. Pretreatment of HepG2 cells and primary hepatocytes with the protonphore FCCP (which leads to a collapse in the trans-membrane pH gradient) led to a significant reduction in the initial rate of nicotinic acid uptake. These findings suggest the involvement of a nicotinic acid-H ϩ cotransport (and/or nicotinic acid/OH Ϫ exchange) process in the vitamin transport process in human liver cells. The source of H ϩ needed for driving nicotinic acid uptake into liver cells could be provided by the activity of Na ϩ /H ϩ exchangers, which are abundantly expressed in hepatocytes (4, 11, 21) . In contrast to the role of incubation buffer pH (i.e., H ϩ ), no role for extracellular Na ϩ in nicotinic acid uptake by HepG2 cells was found, as isoosmotically replacing this monovalent cation with an equimolar concentration of other monovalent cations or with mannitol failed to affect the initial rate of uptake of this vitamin. This conclusion was further supported by the finding of a lack of an effect of pretreatment of HepG2 cells with ouabain (an inhibitor of Na ϩ -K ϩ -ATPase) on the initial rate of nicotinic acid uptake.
Our investigations provided evidence that the transport of nicotinic acid into HepG2 cells and human primary hepatocytes involves a carrier-mediated process. This conclusion is based on the findings of saturation in the initial rate of nicotinic acid uptake as a function of concentration, the ability of unlabeled nicotinic acid to cis-inhibit the initial rate of [ 3 H]nicotinic acid uptake, and the trans-stimulation in [ 3 H]nicotinic acid efflux from preloaded cells by extracellular unlabeled vitamin. The apparent K m of the saturable component was determined to be 0.73 Ϯ 0.16 M, which suggests a role for this system in the transport of physiological concentrations of the vitamin that exist in human plasma at a range of 0.1-1 M (9, 29) .
The nicotinic acid membrane transport system of HepG2 cells and human primary hepatocytes was found to be specific for the vitamin, as only biologically active nicotinamide was able to inhibit the initial rate of [ 3 H]nicotinic acid uptake. The inability of 5-methyl-1H-pyrazole-3-carboxylic acid [a highaffinity ligand for the nicotinic acid receptor (32) ] to inhibit nicotinic acid uptake by HepG2 cells is in line with recently published data showing lack of expression of the nicotinic acid receptor in liver tissue (32) , and together they clearly suggest that this receptor plays no role in liver uptake of the vitamin. We also tested the effect of a host of unrelated carboxylic acids on the initial rate of negatively charged nicotinic acid uptake, but none were found to cause a significant effect, further establishing the specific nature of the process. A number of the tested organic anions were substrates or inhibitors (phloretin and ␣-cyano-4-hydroxycinnamate) for monocarboxylate transporter (MCT) systems (9, 12) . Thus, because these compounds did not affect nicotinic acid uptake and since affinity of MCT systems is low [i.e., in the millimolar range (9, 12)], it is reasonable to assume that MCT systems are not involved in the uptake of physiological concentrations of nicotinic acids by human liver cells.
Following functional identification of a nicotinic acid transport system in human liver cells, we tested the possible regulation of the transport process by intracellular and extracellular factors. The effect of intracellular factors was tested by examining the effect of pretreatment of HepG2 cells with modulators of the PKA-, PKC-, PTK-, and Ca 2ϩ /calmodulin-mediated pathways on the initial rate of nicotinic acid uptake. The results showed that while the PKA-, PKC-, and PTK-mediated pathways had no role in the regulation of nicotinic acid uptake by HepG2 cells, a possible role for the Ca 2ϩ /calmodulin-mediated pathway was observed, as inhibitors of this pathway inhibited nicotinic acid uptake by these cells. This inhibition in nicotinic acid uptake was also observed when human primary hepatocytes were used. The molecular mechanism(s) involved in the Ca 2ϩ /calmodulin mediated effect on nicotinic acid uptake by human liver cells is not clear and requires further investigation. Whether the nicotinic acid uptake process of HepG2 cells is adaptively regulated by the substrate level in the extracellular medium was also examined by testing the effect of maintenance of cells in the presence of a high concentration of nicotinic acid or its metabolically active derivative nicotinamide on the initial rate of [ 3 H]nicotinic acid uptake. The results, however, showed no such regulation in the vitamin Values are means Ϯ SE of at least 3 separate uptake determinations. HepG2 cells were treated as described in Table 1 with the exception that cells were pretreated for 1 h with the different modulators.
uptake process in HepG2 cells, a finding that is in contrast to the adaptive regulation that occurs in the uptake of other water-soluble vitamins (e.g., folate, riboflavin, and pyridoxine) by their levels in the extracellular environment (24 -26) . Whether this lack of adaptive regulation in nicotinic acid uptake is related to the ability of hepatocytes to synthesize some nicotinic acid (compared with their inability to synthesize other vitamins) is not clear.
In summary, these results show, for the first time, the existence of an acidic pH-dependent, high-affinity, and specific carrier-mediated system for nicotinic acid transport in human liver cells. This system operates in the physiological micromolar range and appears to be regulated by an intracellular Ca 2ϩ /calmodulin-mediated pathway.
GRANTS
This work was supported by a grant from the Department of Veterans Affairs and by National Institute of Diabetes and Digestive and Kidney Diseases Grants DK-56061, DK-58057, and DK-64165.
